Rallybio Lands $50M Termination Fee, Unveils Avenzo Merger That Slashes Legacy Stake to ~2.8%
RLYB has more than doubled off its 52-week low of $3.2.
Summary
Rallybio's Q2 2026 10-Q reports a $50M termination fee from the failed Candid merger and unveils a new reverse merger with Avenzo Therapeutics that will leave existing Rallybio stockholders with only ~2.8% of the combined company.
Key Events · Earnings and Guidance · RLYB
-
$50M Termination Fee Boosts Cash
A $50 million termination fee from Candid Therapeutics, received after the merger agreement was terminated on May 3, 2026, drove net income to $43.7 million for Q2 2026 and pushed cash to $92.8 million as of June 30, 2026.
-
New Reverse Merger with Avenzo
On May 31, 2026, Rallybio entered a definitive merger agreement with Avenzo Therapeutics, a clinical-stage oncology company. Under the exchange ratio, pre-merger Rallybio stockholders will own only ~2.8% of the combined company, while Avenzo equityholders (excluding concurrent financing investors) will hold ~56.6% and concurrent financing investors ~40.6%.
-
$215M Concurrent Financing by Avenzo
In connection with the merger, Avenzo entered a subscription agreement to sell shares for $215 million immediately prior to closing, providing significant capital to the combined company.
-
Cash Distribution to Legacy Holders
Prior to closing, Rallybio will declare distributions of its net cash (estimated at a $15 million valuation after giving effect to the distribution) to existing Rallybio stockholders, with the remainder of legacy assets tied to contingent value rights.
Analysis · RLYB · Life Sciences
The Q2 2026 10-Q from Rallybio discloses a $50 million termination fee stemming from the failed Candid merger, which lifts cash to $92.8 million and produces net income of $43.7 million. More importantly, it lays out a new reverse merger with Avenzo Therapeutics that will severely dilute existing Rallybio stockholders to roughly 2.8% of the combined entity, while Avenzo investors inject $215 million in concurrent financing. The deal is expected to close before year-end, and Rallybio plans to distribute its net cash to legacy holders pre-closing. This fundamentally reshapes the investment thesis — Rallybio is effectively becoming Avenzo, with legacy assets reduced to contingent value rights.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $16.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.5M. The 52-week trading range was $3.20 to $17.57. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.